In parallel, as a prognostic factor, the more strength of sPDL1 compared with NLR, which is a very pragmatic, easily applicable clinical factor for the practice on advanced biliary tract cancer patients, should be studied. This evidence concerns the gene SPDL1 and biliary tract neoplasm.